当前位置： SCI文献检索 > EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY期刊下所有文献 > Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients.

Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients.

Abstract：

PURPOSE:To analyze the clinical features and risk factors of tigecycline-associated hypofibrinogenaemia and study whether cefoperazone/sulbactam combined with tigecycline aggravates coagulopathy or hypofibrinogenaemia. METHODS:A retrospective case-control study of patients with severe infection who were treated with tigecycline was conducted. Patients were assigned to the hypofibrinogenaemia group (< 2.0 g/L) and normal fibrinogen (normal) group (≥ 2.0 g/L) to assess the clinical features of patients with tigecycline-associated hypofibrinogenaemia. The traits of patients treated with cefoperazone/sulbactam in the hypofibrinogenaemia group were also analyzed. RESULTS:In total, 127 patients were enrolled in the study, including 71 patients with hypofibrinogenaemia and 56 patients with normal fibrinogen levels. Hypofibrinogenaemia developed at a median of 6 (4-8) days after tigecycline treatment, and the fibrinogen level returned to normal at a median of 3 (3-5) days after tigecycline discontinuation. In the multivariate analysis, intra-abdominal infection (p = 0.005), fibrinogen level at tigecycline initiation (p < 0.001), maintenance dose (p = 0.039), and treatment duration (p = 0.002) were found to be related to hypofibrinogenaemia. Treatment with cefoperazone/sulbactam was not associated with hypofibrinogenaemia (p = 0.681), but patients treated with cefoperazone/sulbactam had a higher incidence of coagulopathy (p = 0.009) and needed more blood products (p = 0.003) than those treated without cefoperazone/sulbactam. CONCLUSION:Tigecycline-associated hypofibrinogenaemia often developed on the 6th (4th-8th) day of tigecycline use and was associated with intra-abdominal infection, fibrinogen level at tigecycline initiation, maintenance dose, and treatment duration of tigecycline but not cefoperazone/sulbactam.

journal_name

Eur J Clin Pharmacol

journal_title

European journal of clinical pharmacology

authors

Hu J,Xiao YH,Zheng Y,Lai YX,Fang XL,Fang Q

doi

10.1007/s00228-020-02860-w

subject

Has Abstract

pub_date

2020-07-01 00:00:00

pages

913-922

issue

eissn

0031-6970

issn

1432-1041

pii

10.1007/s00228-020-02860-w

journal_volume

pub_type

杂志文章

在线工具

Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients.